ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1729

Ribophorin II Is Involved in the Tissue Factor Expression Mediated by Phosphatidylserine-Dependent Antiprothrombin Antibody On Monocytes

Yuichiro Fujieda1, Olga Amengual1, Yusaku Kanetsuka1, Toshio Odani1, Kotaro Otomo1, Kenji Oku2, Toshiyuki Bohgaki1, Tetsuya Horita1, Shinsuke Yasuda1, Kimiko Kuroki3, Katsumi Maenaka3, Masaki Matsumoto4, Shigetsugu Hatakeyama5 and Tatsuya Atsumi6, 1Hokkaido University,Medicine II, Sapporo, Japan, 2Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 3Hokkaido University,Laboratory of Biomolecular Science, Sapporo, Japan, 4Kyusyu University,Divison of proteomics, Multi-scale Reserch Center for Prevention of Medical Science, Fukuoka, Japan, 5Hokkaido University,Biochemistry, Sapporo, Japan, 6Medicine II, Hokkaido University,Medicine II, Sapporo, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid syndrome and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antiphospholipid syndrome (APS) is characterized by thrombosis and the presence of antiphospholipid antibodies (aPL). Tissue factor (TF), the major initiator of the extrinsic coagulation system, is induced on monocytes by aPL in vitro. Phosphatidylserine-dependent antiprothrombin antibody (aPS/PT) recognized the phophatidylserin/prothrombin (PS/PT) complex, and is highly associated with APS. We have previously reported that 231D, a mouse monoclonal aPS/PT, induced TF expression on monocytes. However, the cell surface receptor for the binding of PS/PT complex leading to the activation of cell signaling pathways and TF expression is unknown.To investigate the membrane protein involved in the binding of Prothrombin (PT) and aPS/PT to cell surface and the induction of TF expression on monocytes.

Methods: 1) Unknown PT binding membrane protein on monocyte was screened by a proteomics technique using immunoaffinity chromatography and mass spectrometric analysis. FLAG-tagged human PT (FLAG-PT) was constructed and the expression vector encoding FLAG-PT was transfected into HEK293T cells. The expression of full length FLAG-PT in the culture supernatant was evaluated by immunoblotting. RAW 264.7 cells with FLAG-PT were incubated and applied for affinity chromatography with anti-FLAG antibody-conjugated Sepharose beads. The purified fraction was subjected to SDS-PAGE and detected with Coomassie Brilliant Blue staining. Immunopurified proteins were analyzed by an online-nano LC-MS/MS. Obtained MS/MS data were searched against nrNCBI database MASCOT algorithm. 2) The binding between PT and Ribophorin II (RPN2) was analyzed by enzyme-linked immunosorbent assay (ELISA) with purified His-tagged human RPN2 (His-RPN2). 3) RPN2 expression on cell surface of CD14 positive cells and RAW 264.7 cells was analyzed by flowcytometoric analysis. 4) To elucidate the role of RPN2 in TF mRNA expression, RAW 264.7 cells treated with RPN2 small interfering RNA (siRNA) expression and TF mRNA was determined by real-time PCR.

Results: 1) Amoung many proteins confirmed in the spectrometry, RPN2 a part of an N-oligosaccharyl transferase complex was identified as the candidate molecule to be the membrane protein involved in the PT binding to cell surface. 2) The binding between PT and His-RPN2 was confirmed by ELISA. 3) Flowcytometoric analysis showed the expression of RPN2 on monocyte cell surface. 4) Treated cells with RPN2 siRNA showed significantly reduction of the TF expression mediated by PT and 231D (Fig).  

Conclusion: RPN2 was detected as a major PT binding molecule by proteomics analysis.  RPN2 may be involved in the pathophysiology of thrombosis in patients with APS.

 

�à–¾: C:UsersfujiedaDesktopACR figure1.gif

Fig.  RAW264.7 cells transfected with RPN2-siRNA were incubated with monoclonal aPS/PT (231D).  TF mRNA was quantitated by Real Time PCR.


Disclosure:

Y. Fujieda,
None;

O. Amengual,
None;

Y. Kanetsuka,
None;

T. Odani,
None;

K. Otomo,
None;

K. Oku,
None;

T. Bohgaki,
None;

T. Horita,
None;

S. Yasuda,
None;

K. Kuroki,
None;

K. Maenaka,
None;

M. Matsumoto,
None;

S. Hatakeyama,
None;

T. Atsumi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ribophorin-ii-is-involved-in-the-tissue-factor-expression-mediated-by-phosphatidylserine-dependent-antiprothrombin-antibody-on-monocytes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology